Navigation Links
Study identifies drug resistance of CLL in bone marrow and lymph nodes
Date:12/6/2010

ORLANDO In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.

To uncover the reasons for CLL's resilience in the marrow and lymph nodes, the researchers employed a technique called BH3 profiling, which had been devised by senior author Anthony Letai, MD, PhD, and his Dana-Farber colleagues in 2005. The technique makes it possible to identify cancer cells that are less likely to undergo mitochondrial apoptosis (a form of programmed cell death involving cell structures called mitochondria) because of alterations in the Bcl-2 family of proteins. These abnormalities can make such cells less susceptible to both standard chemotherapy and novel, targeted agents.

In the current study, Letai and his associates found that when CLL cells from patients were grown with non-cancerous support cells from the bone marrow and lymph nodes, the CLL cells were more resistant to apoptosis and hence harder to kill with treatment than were CLL cells from the bloodstream. Using BH3 profiling, they discovered that although circulating CLL cells were likely to die by mitochondrial apoptosis in response to treatment, CLL cells grown among non-cancerous cells were much less likely to die this way. The presence of these normal cells, known as stroma, apparently helped the CLL cells survive, despite receiving treatment that would otherwise have resulted in their death.

"We hope that by clearly identifying the ability of stromal cells to reduce the CLL cells' capability to undergo apoptosis, we can exploit strategies to selectively target the 'help' that stromal cells give to CLL cells," says Letai.


'/>"/>

Contact: Teresa Herbert
Teresa_Herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Teen Dating Violence is Common, Study Finds
2. Daily Sunscreen Use Does Protect from Melanoma, Study Finds
3. Kids Team Sports Often Lacking in Exercise, Study Finds
4. Penn study on skin formation suggests strategies to fight skin cancer
5. Gene Therapy Corrected Rare Bleeding Disorder: Study
6. Study finds family acceptance of LGBT youth protects against depression, substance abuse, suicide
7. U.S. Needs National Registry for Joint Replacement Devices: Study
8. Economist honored for study on impact of new cancer drugs on life expectancy
9. NIH study suggests that early detection is possible for prion diseases
10. Female Vets Much More Likely to Commit Suicide, Study Finds
11. Study Suggests Link Between Crohns Disease and PTSD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: